New Stock News | The prospectus for the Hong Kong IPO of German Magnesium Medicine has been invalidated.

De Magnesia Pharmaceutical Co., Ltd. (referred to as De Magnesia Pharmaceuticals) submitted its Hong Kong IPO prospectus on April 22, which expired after 6 months on October 22, with Huatai International as the exclusive sponsor at the time of submission. The prospectus shows that De Magnesia Pharmaceuticals is an innovative pharmaceutical company specializing in skin health, focusing on the research, production, and sales of prescription drugs for skin and dermatological skincare products, dedicated to providing comprehensive solutions for skin health from prevention, treatment to long-term care. The company has established a rich and differentiated product portfolio, covering major skin diseases with significant unmet clinical needs. According to the Zuo Shi Consultancy report, among innovative drug companies in China, the number of indications covered by the company's products for skin diseases ranks first, and in 2024, the company's revenue generated from prescription drugs for skin also ranks first.